The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC

(2019) Michael Trauner et al.   HEPATOLOGY

SAT-337-Evaluation of anti-fibrotic properties of OCA and INT-767 in an in vitro system of NAFLD

(2019) Beatrice Anfuso et al.   JOURNAL OF HEPATOLOGY

Changes in HVPG predict hepatic decompensation in patients who achieved SVR to IFN ‐free therapy

(2019) Mattias Mandorfer et al.   HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH

(2018) E. Lawitz et al.   JOURNAL OF HEPATOLOGY

Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis

(2018) Toshihiro Goto et al.   Scientific Reports

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis

(2018) Jiyu Zhou et al.   Acta Pharmaceutica Sinica B

Beta adrenergic blockade and decompensated cirrhosis

(2017) Thomas Reiberger et al.   JOURNAL OF HEPATOLOGY

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

(2017) Philipp Schwabl et al.   JOURNAL OF HEPATOLOGY

The epidemiology of non-alcoholic fatty liver disease

(2017) Stefano Bellentani   LIVER INTERNATIONAL

Liver Capsule: FXR agonists against liver disease

(2016) Claudia D. Fuchs et al.   HEPATOLOGY

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

(2016) Juan P. Arab et al.   HEPATOLOGY

Fxr Agonism by Gs-9674 Decreases Steatosis and Fibrosis in a Murine Model of Nash

(2016) J.T. Liles et al.   JOURNAL OF HEPATOLOGY

Tissue Inhibitors of Metalloproteinase-1 and 2 and Obesity Related Non-Alcoholic Fatty Liver Disease: Is There a Relationship?

(2015) Rokaya Abdelaziz et al.   DIGESTION

Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH

(2015) Stefan Traussnigg et al.   DIGESTIVE DISEASES

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension

(2015) Rajeshwar P. Mookerjee et al.   JOURNAL OF HEPATOLOGY

Expanding consensus in portal hypertension

(2015) Roberto de Franchis   JOURNAL OF HEPATOLOGY

Nonselective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis

(2014) Mattias Mandorfer et al.   GASTROENTEROLOGY

O15 EFFECTS OF THE FXR AGONIST OBETICHOLIC ACID ON HEPATIC VENOUS PRESSURE GRADIENT (HVPG) IN ALCOHOLIC CIRRHOSIS: A PROOF OF CONCEPT PHASE 2A STUDY

(2014) R. Mookerjee et al.   JOURNAL OF HEPATOLOGY

Propranolol, a β-adrenoceptor antagonist, worsens liver injury in a model of non-alcoholic steatohepatitis

(2013) Chad McKee et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

(2013) Len Verbeke et al.   HEPATOLOGY

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH

(2009) Fusako Takayama et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver

(2008) Scott L. Friedman   PHYSIOLOGICAL REVIEWS